Since the outbreak of COVID-19, vaccination has been generally accepted as the most economical and most effective measure for prevention. For domestic vaccine R&D and manufacturing enterprises, this means an all-round competition of R&D and industrialization capabilities—who masters the hardcore technology, scales up R&D achievements quickly and smoothly, wins the race against time to stop the spreading of virus, and becomes the leader of vaccine.

Another domestic 13-valent pneumococcal polysaccharide conjugate vaccine (hereinafter “PCV13”) has entered Phase III clinical trials. It is learned that this vaccine is a major vaccine product across the globe, which is only supplied by Pfizer, Walvax and BIOKANGTAI and in great demand. With this new product entering the final stage of clinical research, more stories are going to be written in the market.
On the 14th of this month, the Ethics Committee for Vaccine Clinical Trials of the Yunnan Provincial Center for Disease Prevention and Control issued an ethical approval for Phase III clinical trials of this vaccine, marking the beginning of its Phase III clinical trials. According to public data, this vaccine is independently researched and developed by AIM Vaccine Co., Ltd.

On September 12, AIM Vaccine, China’s No.1 private-owned vaccine industrial group, submitted its prospectus to the main board of HKSE, planning to use raised fund for enriching vaccine R&D pipelines, constructing production facilities, sales and marketing campaigns, with Goldman Sachs, CICC, China Securities International, and MACQUARIE as co-sponsors. As a leading enterprise of China’s vaccine industry, AIM Vaccine is the only Chinese vaccine manufacturer with mRNA platform technology and a vaccine in clinical trials and under development using mRNA technology.

According to the disclosure of HKSE on September 12, AIM Vaccine has submitted its prospectus to the main board. Previously, AIM Vaccine has officially announced its big progress—its mRNA COVID-19 vaccine has completed low-dose and medium-dose enrollment of adults at the Phase I Clinical Research Laboratory of Shulan (Hangzhou) Hospital, and the preliminary results indicated safety and good tolerance after vaccination.